Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02633163 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)

A Phase 2 study of Systemic Lupus Erythematosus, sponsored by Medical University of South Carolina.

Completed
Registry status
Phase 2
Development phase
81
Enrollment target
9
Study locations

NCT02633163 is a Phase 2 study of Systemic Lupus Erythematosus that has completed, run by Medical University of South Carolina. The registered enrollment target is 81 participants, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (79% lower). The trial reports 9 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02633163, a Phase 2 study of Systemic Lupus Erythematosus, has completed, sponsored by Medical University of South Carolina.

COMPLETED
Registry status
Phase 2
Development phase
81 participants
Enrollment target
9
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care respond better than patients receiving placebo infusion plus standard of care.

Conditions Studied

Systemic Lupus Erythematosus

Interventions

  • DRUG Low Dose Mesenchymal Stem Cells (MSCs)
  • DRUG High Dose Mesenchymal Stem Cells (MSCs)
  • DRUG Placebo Infusion

Study Locations (9)

California

  • Cedars-Sinai Medical Center - Los Angeles
  • University of California - San Diego - San Diego

New York

  • The Feinstein Institute for Medical Research - Manhasset
  • University of Rochester Medical Center - Rochester

Georgia

  • Emory University - Atlanta

Illinois

  • Northwestern University - Chicago

North Carolina

  • University of North Carolina at Chapel Hill - Chapel Hill

Oklahoma

  • Oklahoma Medical Research Foundation - Oklahoma City

South Carolina

  • Medical University of South Carolina - Charleston

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2018-11-18
Est. Completion 2026-02-03
Phase Phase 2

Sponsor

Medical University of South Carolina

755 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02633163

The ClinicalTrials.gov registry entry for NCT02633163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 380-participant average among 99 other Systemic Lupus Erythematosus trials with a reported enrollment target (79% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Systemic Lupus Erythematosus appearing as the primary indexed condition, and to 3 interventions - of which Low Dose Mesenchymal Stem Cells (MSCs) is the first listed.

NCT02633163 reports 9 study locations spanning 7 distinct geographic areas - top geographies include California, New York, Georgia.

Frequently Asked Questions

What is clinical trial NCT02633163 about?

NCT02633163 is a clinical study titled "Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)". The purpose of this study is to evaluate the efficacy and safety of mesenchymal stem cells (MSCs) obtained from umbilical cords for the treatment of adults with systemic lupus erythematosus (SLE). The goal of this study is to determine if patients receiving an MSC infusion plus standard of care resp...

What is the current status of trial NCT02633163?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2018-11-18. Estimated completion is 2026-02-03.

What conditions does trial NCT02633163 study?

This clinical trial studies the following conditions: Systemic Lupus Erythematosus.

What interventions are being tested in trial NCT02633163?

The interventions under investigation include: Low Dose Mesenchymal Stem Cells (MSCs) (DRUG), High Dose Mesenchymal Stem Cells (MSCs) (DRUG), Placebo Infusion (DRUG).

Who is sponsoring clinical trial NCT02633163?

This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02633163 being conducted?

This trial has 9 study locations across California, Georgia, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Systemic Lupus Erythematosus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Systemic Lupus Erythematosus

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.